Swiss Virtual Clinic uniquely designed for Cataract Surgery
If you or someone you know is dealing with cataract surgery, sorting through the sheer volume of information can be overwhelming. Reliable details aren’t always easy to find, which is exactly why the Swiss Virtual Clinic was created by Swiss Advanced Vision (SAV-IOL SA). This first-of-its-kind online platform offers tailored access for both patients and eyecare professionals, making it simpler than ever to access the right information in one place.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250320758061/en/
Cataract surgery is one of the most common eye procedures, yet for many patients, it still feels like a mystery. The Swiss Virtual Clinic makes things clearer with an easy-to-use interface that explains the procedure, potential concerns, and what to expect - all for free on sav-iol.com.
For eyecare professionals, keeping up with the latest in cataract surgery can be a challenge. From available tools to technical queries, finding information takes time - time that could be better spent focusing on patients. The newly launched Swiss Virtual Clinic offers a dedicated section, packed with valuable resources to support their work. And the best part? It’s designed to be intuitive and regularly updated so professionals can find exactly what they need when they need it. Since this pro section contains specialized medical content, users will need to register to ensure that only experts in the field can engage with the materials.
This launch is a major evolution and reinforces SAV-IOL’s portfolio built on innovation, quality, and precision. “And it marks just the beginning. More features are already in the pipeline as we continue adapting to the evolving needs of ophthalmic surgeons and their patients,” says Alexandre Pascarella, CEO of Swiss Advanced Vision.
If you’re an eyecare professional looking to save time and streamline your practice, now’s the perfect moment to join the Swiss Virtual Clinic. Subscriptions are open on sav-iol.com! For those attending the APAO Congress this year, there’s an opportunity to experience exclusive insights firsthand. From 3rd to 6th April, Swiss Advanced Vision will be showcasing the latest innovation at its booth in New Delhi.
Since 2009, SAV-IOL develops and markets advanced EDOF IOLs globally. Its LUCIDIS and EDEN lenses, powered by Instant Focus technology, provide continuous vision from near to intermediate and far distances.
The Swiss Virtual Clinic opens the door to brand new tailored services accompanying surgeons and their medical teams as well as patients to approach cataract surgery in a truly disruptive way.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250320758061/en/
Contacts
Hülya AYDIN
Brand & Marketing Manager
hulya.aydin@sav-iol.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SBC Medical Group Holdings Inc. Announces Fourth Quarter and Full Year 2024 Financial Results28.3.2025 13:00:00 EET | Press release
SBC Medical Group Holdings Incorporated (NASDAQ: SBC, “SBC Medical” or the “Company”), a global owner, operator and provider of management services and products to cosmetic treatment centers, today announced its financial results for -the three months ended December 31, 2024 and full year 2024. Fourth Quarter 2024 Highlights Total revenues were $44 million, representing a 29% year-over-year decrease. Gross profit was $34 million, representing a 22% year-over-year decrease. Income from operations was $5 million, representing an 80% year-over-year decrease. EBITDA1, which is calculated by adding depreciation and amortization expense and impairment loss to income from operations was $21 million, representing a 22% year-over-year decrease. EBITDA margin1was 47% for the fourth quarter of 2024, compared to 43% for the fourth quarter of 2023. Net income attributable to SBC Medical Group was $7 million, representing a 54% year-over-year decrease. Earnings per share, which is defined as net inc
SINOVAC Announces New Board Member and Chairman of the Audit Committee28.3.2025 13:00:00 EET | Press release
Sinovac Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that its board of directors (the “Board”) has appointed Sven H. Borho, CFA, as director to the Board to fill in a vacancy created by a recent resignation. As a qualified audit committee financial expert under Nasdaq Rule 5605, Mr. Borho has also been elected as the Chair of the Audit Committee of the Board. Mr. Borho is a founder and Managing Partner of OrbiMed and has over 30 years of experience investing in the healthcare sector. OrbiMed is a leading healthcare investment firm with approximately $17 billion in assets under management. OrbiMed invests globally across the healthcare industry, from start-ups to large multinational corporations, through a range of private equity funds, public equity funds and royalty/credit funds. OrbiMed funds have been shareholders of SINOVAC since 2013 and currently hold over 2.7 million shares. Following this appo
European Medicines Agency (EMA) Validates Henlius and Organon Filing for Perjeta ® (pertuzumab) Biosimilar Candidate HLX1128.3.2025 12:00:00 EET | Press release
Shanghai Henlius Biotech, Inc. (2696.HK) and Organon (NYSE: OGN) today announced that the European Medicines Agency (EMA) has validated the marketing authorization application (MAA) for HLX11, an investigational biosimilar of Perjeta® (pertuzumab). Pertuzumab has been approved in various countries and regions in combination with trastuzumab and chemotherapy for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory or early-stage breast cancer, and adjuvant treatment for certain HER2-positive early breast cancer, among other indications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250328881021/en/ The submission was based on a multicenter, randomized, double-blind, parallel-controlled phase 3 clinical study (NCT05346224) aimed to compare the efficacy and safety of HLX11 with reference Perjeta® (pertuzumab) as a neoadjuvant therapy in patients with HER2-positive, HR-negative early-stage, o
European DataWarehouse is Awarded Data Provider of the Year for the Fifth Time28.3.2025 09:46:00 EET | Press release
European DataWarehouse (EDW) is pleased to announce it was named Data Provider of the Year at the 2025 GlobalCapital European Securitization Awards in London. The award ceremony recognises the outstanding achievements in European structured finance and winners are selected by popular vote from industry participants. As defined by GlobalCapital, the program celebrates “the very best in the market, as chosen by the market”. This is the fifth time that EDW has won the prestigious Data Provider of the Year award, having also been awarded the honour in 2019, 2022, 2023 and 2024! Dr. Christian Thun, CEO of EDW, stated: “Receiving this award for the fifth time is a testament to the trust and recognition our team has earned within the European securitisation market. This achievement highlights our ongoing commitment to excellence and industry leadership.” Prof. José Manuel González-Páramo, Chairman of EDW, later commented: “EDW continues to stand as a trusted partner in the securitisation mark
W. R. Berkley Corporation Confirms Mitsui Sumitomo Insurance Co. Intends to Purchase 15% of the Company’s Shares in Open Market or Private Transactions From Third Parties28.3.2025 08:48:00 EET | Press release
W. R. Berkley Corporation (NYSE: WRB) (the “Company”) today confirmed that Mitsui Sumitomo Insurance Co., Ltd. (“MSI”), a leading Japanese property and casualty insurance carrier, has entered into an arrangement (the “Investment and Voting Arrangement”) with a company owned by members of the Berkley family and trusts for their benefit (collectively, the “Berkley Family”) providing for MSI to purchase 15% of the Company’s outstanding common stock (the “Common Stock”) through open market purchases or private transactions with third parties. The Berkley Family will not be selling any of its Common Stock to MSI, nor will MSI be purchasing any shares from the Company as part of the arrangement. Under the terms of the agreements being entered into between MSI and the Berkley Family, once MSI acquires 4.9% of the outstanding Common Stock, MSI agrees to vote those shares pursuant to the recommendations of the Berkley Family, except in limited circumstances where the Berkley Family will vote th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom